Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 67-74 |
| Seitenumfang | 8 |
| Fachzeitschrift | Radiotherapy and Oncology |
| Jahrgang | 91 |
| Ausgabenummer | 1 |
| Frühes Online-Datum | 8 Jan. 2009 |
| Publikationsstatus | Veröffentlicht - Apr. 2009 |
Abstract
Background: The objective of this systematic review was to summarise the current evidence concerning radiosurgical treatment (SRS) of newly diagnosed brain metastasis and to compare SRS as a single or additional treatment to treatment alternatives with regard to medical effectiveness and safety. Methods: A structured search of electronic databases was performed to identify relevant publications from 2002 through 2007. Studies targeting patients with brain metastases were included. Standardised quality assessment and data extraction were performed. Results: Of 1496 publications, 16 studies were included. The mean survival in most studies was less than 12 months. There was evidence that SRS plus WBRT was associated with improved local tumour control and neurological functioning compared to either treatment alone. Only in patients with single metastasis, this resulted in improved survival. There was inconclusive evidence when comparing SRS to WBRT, Neurosurgery (NS) or Hypofractionated Radiotherapy (HCSRT). The Quality of life (Qol) was not investigated. Conclusion: SRS plus WBRT was associated with improved local tumour control and neurological functioning compared to either treatment alone. Only in certain patients, this resulted in improved survival. Methodologically rigorous studies are therefore warranted to investigate further treatment options, and in view of the poor prognosis, to investigate Qol and neurological functioning.
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Hämatologie
- Medizin (insg.)
- Onkologie
- Medizin (insg.)
- Radiologie, Nuklearmedizin und Bildgebung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Radiotherapy and Oncology, Jahrgang 91, Nr. 1, 04.2009, S. 67-74.
Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Forschung › Peer-Review
}
TY - JOUR
T1 - Stereotactic radiosurgery for the treatment of brain metastases
AU - Müller-Riemenschneider, Falk
AU - Bockelbrink, Angelina
AU - Ernst, Iris
AU - Schwarzbach, Christoph
AU - Vauth, Christoph
AU - von der Schulenburg, J. Matthias Graf
AU - Willich, Stefan N.
N1 - Funding Information: This study was commissioned and in part funded by the German Agency for Health Technology Assessment at the German Institute of Medical Documentation and Information (DAHTA@DIMDI), a subsidiary of the German Federal Ministry of Health. Funding organizations or sponsors had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
PY - 2009/4
Y1 - 2009/4
N2 - Background: The objective of this systematic review was to summarise the current evidence concerning radiosurgical treatment (SRS) of newly diagnosed brain metastasis and to compare SRS as a single or additional treatment to treatment alternatives with regard to medical effectiveness and safety. Methods: A structured search of electronic databases was performed to identify relevant publications from 2002 through 2007. Studies targeting patients with brain metastases were included. Standardised quality assessment and data extraction were performed. Results: Of 1496 publications, 16 studies were included. The mean survival in most studies was less than 12 months. There was evidence that SRS plus WBRT was associated with improved local tumour control and neurological functioning compared to either treatment alone. Only in patients with single metastasis, this resulted in improved survival. There was inconclusive evidence when comparing SRS to WBRT, Neurosurgery (NS) or Hypofractionated Radiotherapy (HCSRT). The Quality of life (Qol) was not investigated. Conclusion: SRS plus WBRT was associated with improved local tumour control and neurological functioning compared to either treatment alone. Only in certain patients, this resulted in improved survival. Methodologically rigorous studies are therefore warranted to investigate further treatment options, and in view of the poor prognosis, to investigate Qol and neurological functioning.
AB - Background: The objective of this systematic review was to summarise the current evidence concerning radiosurgical treatment (SRS) of newly diagnosed brain metastasis and to compare SRS as a single or additional treatment to treatment alternatives with regard to medical effectiveness and safety. Methods: A structured search of electronic databases was performed to identify relevant publications from 2002 through 2007. Studies targeting patients with brain metastases were included. Standardised quality assessment and data extraction were performed. Results: Of 1496 publications, 16 studies were included. The mean survival in most studies was less than 12 months. There was evidence that SRS plus WBRT was associated with improved local tumour control and neurological functioning compared to either treatment alone. Only in patients with single metastasis, this resulted in improved survival. There was inconclusive evidence when comparing SRS to WBRT, Neurosurgery (NS) or Hypofractionated Radiotherapy (HCSRT). The Quality of life (Qol) was not investigated. Conclusion: SRS plus WBRT was associated with improved local tumour control and neurological functioning compared to either treatment alone. Only in certain patients, this resulted in improved survival. Methodologically rigorous studies are therefore warranted to investigate further treatment options, and in view of the poor prognosis, to investigate Qol and neurological functioning.
KW - Brain metastasis
KW - Stereotactic radiosurgery
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=62549146158&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2008.12.001
DO - 10.1016/j.radonc.2008.12.001
M3 - Review article
C2 - 19135750
AN - SCOPUS:62549146158
VL - 91
SP - 67
EP - 74
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
SN - 0167-8140
IS - 1
ER -